Form 4: ADAR1 Capital Management Reports Expiration of Keros Therapeutics Put Options

ADAR1 Capital Management and related entities have filed a Form 4 indicating the expiration of put options on Keros Therapeutics, Inc. common stock, with a strike price of $10, resulting in no beneficial ownership of these derivative securities following the transactions.

Summary

• ADAR1 Capital Management, LLC, ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC, and Daniel Schneeberger are the reporting persons.
• The reporting persons are identified as 10% owners and directors of Keros Therapeutics, Inc. (KROS).
• The filing reports the expiration of put options (obligation to buy) on KROS common stock.
• A total of 1,314 put options expired, representing an underlying obligation to buy 131,400 shares of KROS common stock.
• The put options had a strike price of $10.
• The expiration date for all reported put options was May 16, 2025.
• Following the expiration, the reporting persons hold 0 derivative securities of this type.
• The beneficial ownership is indirect, held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC.
• The reporting persons disclaim beneficial ownership except to the extent of their pecuniary interest.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing (Form 4) reporting the expiration of derivative securities. It does not contain information that would significantly alter the perception of the company's financial health or operational outlook, thus indicating a neutral sentiment.

Positives

• The expiration of the put options means the reporting persons were not obligated to purchase Keros Therapeutics shares at the $10 strike price, implying the market price was likely above $10 at expiration.

Future Outlook

This filing does not provide forward-looking statements or guidance regarding Keros Therapeutics' financial performance or strategic direction.

Management Comments

• "As the investment manager of ADAR1 Partners, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC."
• "As the general partner of ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP."
• "As the manager of ADAR1 Capital Management, LLC and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP and Spearhead Insurance Solutions IDF, LLC."
• "For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise."

Industry Context

This Form 4 filing is a routine disclosure of changes in beneficial ownership of derivative securities by an insider. It does not provide broader industry context or trends.

Stakeholder Impact

• Shareholders: The expiration of these put options means no new shares were acquired by the reporting persons through this mechanism, which is a neutral event for existing share dilution.

Key Dates

Keywords

Keros Therapeutics, KROS, ADAR1 Capital Management, SEC Form 4, Beneficial Ownership, Put Options, Derivative Securities, Insider Trading, Stock Options, Investment Management